Breast Cancer and Breast Health
Episodes 1-16 of 24
Giuseppe Curigliano, MD, PhD
Cynthia Villarreal-Garza, MD, DSc
Komal Jhaveri, MD, FACP
Hiraji Iwata, MD, PhD
- MinuteCE®
Unmet Needs in Endocrine Therapy: Rethinking the HR+/HER2- mBC Treatment Roadmap
1.00 program creditKomal Jhaveri, MD, FACP
- MinuteCE®
Breaking Down the Benchmarks: Pivotal Data on First-Line CDK4/6 Inhibitors
1.00 program creditGiuseppe Curigliano, MD, PhD
Giuseppe Curigliano, MD, PhD
Komal Jhaveri, MD, FACP
Komal Jhaveri, MD, FACP
- MinuteCE®
Doublet or Triplet? A Case-Based Debate in First-Line Choices for HR+/HER2- mBC
1.00 program creditGiuseppe Curigliano, MD, PhD
Komal Jhaveri, MD, FACP
Giuseppe Curigliano, MD, PhD
Komal Jhaveri, MD, FACP
Giuseppe Curigliano, MD, PhD
Cynthia Villarreal-Garza, MD, DSc
Hiraji Iwata, MD, PhD
Kevin Kalinsky MD, MS
Komal Jhaveri, MD, FACP
Javier Cortes, MD, PhD
Hope S. Rugo, MD, FASCO
William J. Gradishar, MD
Erica L. Mayer, MD, MPH
Peter Schmid, FRCP, MD, PhD
Peter Schmid, FRCP, MD, PhD
- MinuteCE®
Adjuvant Treatments for HR+/HER2- EBC: The Role of CDK4/6 and PARP Inhibitors
1.50 program creditsErica L. Mayer, MD, MPH
- Prev
- Next